Cromolyn Sodium

Phase 2Small molecule

UUniversity of California, San Francisco

Cromolyn Sodium is one of 8 small molecule programs targeting Locally-Advanced Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally-Advanced Non-Small Cell Lung CancerNot yet recruiting

Amyotrophic Lateral Sclerosis (ALS)Recruiting

Postural Orthostatic Tachycardia Syndrome (POTS)Not yet recruiting

Locally-Advanced Non-Small Cell Lung CancerPhase 1

Not yet recruiting

Amyotrophic Lateral Sclerosis (ALS)Phase 2

Recruiting

Postural Orthostatic Tachycardia Syndrome (POTS)Phase 1

Not yet recruiting

Competition

Competitive Landscape

12 competitors in Amyotrophic Lateral Sclerosis (ALS)

#DrugCompanyPhaseTrials

Rilutek

AAzurity Pharmaceuticals

Phase 2

1 2

VHB937

Novartis

Phase 2

1 3

Cromolyn Sodium

UUniversity of California, San Francisco

Phase 2

1 4

XT-150

XXalud Therapeutics, Inc.

Phase 1

1 5

NUZ-001

MMerit E. Cudkowicz, MD

Preclinical

1 6

MTP-101C

UUniversity of Minnesota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Amyotrophic Lateral Sclerosis (ALS)

NCT07142291

Q3 2027

Phase 1Not yet recruiting

Locally-Advanced Non-Small Cell Lung Cancer

NCT07675876

Q1 2028

Phase 1Not yet recruiting

Postural Orthostatic Tachycardia Syndrome (POTS)

NCT07757555

Clinical

Trials by Indication[1]

Treatment1 trial

Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

Completed·PPulmotect, Inc.·Phase 1·NCT02566252·16 enrolled

Eosinophilic Esophagitis1 trial

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

Completed·UUniversity of Tennessee·Phase 4·NCT02371941·16 enrolled

Erythema1 trial

An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

Completed·UUniversity of California, San Diego·Phase 1/2·NCT01933464·10 enrolled

Pelvic Pain1 trial

Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction

Completed·NNorthwestern University·Phase 1·NCT03167216·20 enrolled

Aspiration1 trial

Cromolyn Detection of Silent Aspiration

Terminated·UUniversity of California, San Francisco·Phase 1·NCT01841307·16 enrolled

5 more indications

Pneumonia1 trial

Cromolyn Sodium for Treatment of COVID-19 Pneumonia

Terminated·TTexas Tech University Health Sciences Center, El Paso·Phase 3·NCT05077917·22 enrolled

Pruritus1 trial

Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus

Completed·SShiraz University of Medical Sciences·Phase 2·NCT00745199·62 enrolled

Postural Orthostatic Tachycardia Syndrome (POTS)1 trial

Efficacy and Mechanisms of Guanfacine and Cromolyn Sodium in Adults With Postural Orthostatic Tachycardia Syndrome (POTS): A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial. Acronym is DBPOTS (Double Blind POTS)

Not yet recruiting·JJohns Hopkins University·Phase 1·NCT07757555·25 enrolled

Amyotrophic Lateral Sclerosis (ALS)1 trial

A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)

Recruiting·PPhenoNet, Inc.·Phase 2·NCT07142291·105 enrolled

Locally-Advanced Non-Small Cell Lung Cancer1 trial

An Open-Label Pilot Study Evaluating the Safety, Feasibility, and Preliminary Clinical Activity of Inhaled Cromolyn Sodium in Participants With Locally Advanced Lung Cancer

Not yet recruiting·CCarcinex Inc·Phase 1·NCT07675876·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Cromolyn Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cromolyn Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cromolyn Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of California, San Francisco

Cromolyn Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q1 2028

Trials by Indication[1]

Treatment1 trial

Eosinophilic Esophagitis1 trial

Erythema1 trial

Pelvic Pain1 trial

Aspiration1 trial

Pneumonia1 trial

Pruritus1 trial

Postural Orthostatic Tachycardia Syndrome (POTS)1 trial

Amyotrophic Lateral Sclerosis (ALS)1 trial

Locally-Advanced Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News